Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry
Lene Dreyer(Institute for Rheumatic Diseases (Japan)), Henning Locht(Frederiksberg Hospital), Finn Sellebjerg(Kaiser Permanente), Melinda Magyari(University of Copenhagen), Bjarne Laursen(University of Southern Denmark), René Cordtz(Gentofte Hospital)
Cited by 44
Related Papers
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
|Science|2019|1.4k
Worldwide Incidence and Prevalence of Neuromyelitis Optica
|Neurology|2020|303
Childhood body mass index and multiple sclerosis risk: a long-term cohort study
|Multiple Sclerosis Journal|2013|297
Clinical Relevance of Brain Volume Measures in Multiple Sclerosis
|CNS Drugs|2014|293